Purple Biotech (PPBT) Other Non-Current Liabilities (2019 - 2026)

Purple Biotech (PPBT) has 4 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (changed N/A YoY) and the FY2025 annual result came in at $4.1 million, up 253.87% from the prior year.
• Other Non-Current Liabilities fell to $1.9 million in Q1 2026 per PPBT's latest filing, from $4.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.1 million in Q4 2025 and bottomed at $1.1 million in Q4 2024.
• The 4-year median for Other Non-Current Liabilities is $2.2 million (2023), against an average of $2.4 million.
• The widest annual swing landed in 2024, when Other Non-Current Liabilities tumbled 54.37%; it then surged 253.87% in 2025.
• Tracing PPBT's Other Non-Current Liabilities over 4 years: stood at $2.5 million in 2023, then slumped by 54.37% to $1.1 million in 2024, then surged by 253.87% to $4.1 million in 2025, then sank by 53.34% to $1.9 million in 2026.
• Per Business Quant, the three latest PPBT Other Non-Current Liabilities figures stand at $1.9 million (Q1 2026), $4.1 million (Q4 2025), and $1.1 million (Q4 2024).

Peer Comparison